Abstracts tagged "rheumatoid arthritis"

Abstract Number: 493 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
C. Charles-Schoeman¹, Gerd Burmester², P. Nash³, C.a.F. Zerbini⁴, S. Anway⁵, K. Kwok⁶, T. Hendrikx⁷, E. Bananis⁸ and Roy Fleischmann⁹, ¹University of California, Los Angeles, CA, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer BV, Capelle aan den IJssel, Netherlands, ⁸Pfizer Inc, Collegeville, PA, ⁹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the efficacy and safety of tofacitinib 5…
Abstract Number: 2488 • 2014 ACR/ARHP Annual Meeting
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
Roy Fleischmann¹, V Strand², B Wilkinson³, K Kwok⁴ and E Bananis³, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, ²Biopharmaceutical Consultant, Portola Valley, CA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the relationship between clinical measures and patient-reported…
Abstract Number: 1478 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers
M. Lamba¹, R. Wang¹, T. Fletcher², C. Alvey¹, A. Hazra¹, J. Kushner¹, J. Larmann¹ and T. Stock², ¹Pfizer Inc, Groton, CT, ²Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The efficacy and safety of an immediate-release (IR) formulation…
Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
C. Charles-Schoeman¹, A. Dikranian², J. Taylor³, B. Wilkinson⁴, T. Jones⁵, K. Kwok⁶ and C. Nduaka⁴, ¹University of California, Los Angeles, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Anderson Arthritis and Rheumatology Center, Meridian, MS, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…
Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
V. Strand¹, R. Riese², R. Gerber², D. Gruben², A.G. Bushmakin², E.Y. Mahgoub³ and G. Wallenstein², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
Abstract Number: 1462 • 2014 ACR/ARHP Annual Meeting
Cadherin-11 mRNA Expression in the Peripheral Blood of Rheumatoid Arthritis Patients As a Marker of Active Polyarthritis
Petros P. Sfikakis¹, Panagiotis F. Christopoulos^1,2, Aristeidis G. Vaiopoulos^1,2, Kalliopi Fragkiadaki¹, Christina Katsiari³, Violetta Kapsimali⁴, George Lallas¹, Panayiotis Panayiotidis⁴, Pinelopi Korkopoulou⁵ and Michael Koutsilieris², ¹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²Department of Physiology, Athens University Medical School, Athens, Greece, ³Department of Rheumatology, School of Health Sciences, University of Thessaly, Larissa, Greece, ⁴Department of Microbiology, Athens University Medical School, Athens, Greece, ⁵Department of Pathology, Athens University Medical School, Athens, Greece
Background/Purpose: Human rheumatoid arthritis synovial fibroblasts (RASF) implanted subcutaneously in immunodeficient mice trans-migrate through the vasculature and drive the progression from oligo- to poly-articular disease.…
Abstract Number: 461 • 2014 ACR/ARHP Annual Meeting
Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs
P. Bird¹, W. Bensen², B. El-Zorkany³, J. Kaine⁴, B.H. Manapat-Reyes⁵, V. Pascual-Ramos⁶, D. Witcombe⁷, A. Anisfeld⁸, K. Soma⁹, R. Zhang⁹ and K. Thirunavukkarasu⁷, ¹Combined Rheumatology Practice, Sydney, Australia, ²St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada, ³Department of Rheumatology, Cairo University, Cairo, Egypt, ⁴Sarasota Arthritis Research Center, Sarasota, FL, ⁵Section of Rheumatology, Department of Medicine, University of the Philippines - Philippine General Hospital, Manila, Philippines, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷Pfizer Australia, Sydney, Australia, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib has been approved in the US and other countries at the recommended dose 5 mg BID in patients (pts) with rheumatoid arthritis (RA) and…
Abstract Number: 2480 • 2014 ACR/ARHP Annual Meeting
Is there a Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review
Ana M. Ortiz¹, María Piedad Rosario², Carmen Martínez² and Isidoro González-Alvaro¹, ¹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain
Background/Purpose: Since the description of the efficacy of rituximab (RTX) in treating patients with rheumatoid arthritis (RA), the use of this drug has been extended.…
Abstract Number: 1196 • 2014 ACR/ARHP Annual Meeting
Inflammation Develops in a Toll-like Receptor 9-Independent Manner in Experimental Arthritis and Rheumatoid Arthritis
Julie Mussard¹, Matthieu Ribon¹, Gaelle Clavel², Marie-Christophe Boissier³ and Patrice Decker¹, ¹INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ²Fondation Ophtalmologique A. De Rothschild, Paris cedex 19, France, ³INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose Rheumatoid arthritis (RA) is an inflammatory disease of unknown etiology. Toll-like receptor (TLR) 9 recognizes pathogen-derived DNA and even self DNA under certain circumstances.…
Abstract Number: 460 • 2014 ACR/ARHP Annual Meeting
Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program
Jeffrey R. Curtis¹, E.B. Lee², G. Martin³, X. Mariette⁴, K.K. Terry⁵, Y. Chen⁶, J. Geier⁷, J. Andrews⁵, M. Kaur⁶, K. Kwok⁷ and C. Nduaka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Seoul National University College of Medicine, Seoul, South Korea, ³Dermatology and Laser Center of Maui, Kihei, HI, ⁴Paris-Sud University, Paris, France, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The incidence of non-melanoma skin cancer (NMSC) in the tofacitinib…
Abstract Number: 2455 • 2014 ACR/ARHP Annual Meeting
IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression
Erika Noss¹, Sook Kyung Chang², Gerald Watts² and Michael Brenner², ¹Divison of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Interleukin (IL)-6 is an important driver of rheumatoid arthritis (RA) pathology, and synovial fibroblasts are a major source of IL-6 in the RA synovium. …
Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Anna Cooper¹, Johan A. Karlsson² and Anders Gülfe¹, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…
Abstract Number: 471 • 2014 ACR/ARHP Annual Meeting
Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan
Toshihisa Kojima¹, Nobunori Takahashi¹, Koji Funahashi², Shuji Asai², Yutaka Yoshioka², Kenya Terabe², Nobuyuki Asai^2,3, Toki Takemoto², Naoki Ishiguro¹, Atsushi Kaneko⁴, Yuji Hirano⁵, Yuichiro Yabe⁶ and Yasuhide Kanayama⁷, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Nagoya Univeristy Hospital, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁵Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁶Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan, ⁷Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Background/Purpose: Many evidences including clinical trials of biologics lead us earlier and more aggressive treatment strategy for patients with rheumatoid arthritis (RA). It is stated…
Abstract Number: 2447 • 2014 ACR/ARHP Annual Meeting
The Role of TET3-Mediated DNA Demethylation By Pro-Inflammatory Cytokines in Rheumatoid Arthritis
Kazuhisa Nakano¹, Kunihiro Yamaoka¹, Akira Kurozumi², Akio Kawabe², Kaoru Yamagata² and Yoshiya Tanaka³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose In the pathogenesis of Rheumatoid arthritis (RA) RA fibroblast-like synoviocytes (RA FLS) exhibit a unique aggressive phenotype that contributes to the cytokine milieu and…
Abstract Number: 1145 • 2014 ACR/ARHP Annual Meeting
Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², A. Koenig³ and J. Bourret³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: For rheumatoid arthritis (RA) patients (pts) with inadequate response to a TNF inhibitor (TNFi), limited evidence exists from observational studies and indirect comparisons of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].